The biotech stock that went to zero: a terrifying lesson in risk
This is a brutal but essential war story. An analyst slapped a $0 price target on drugmaker Sarepta after a third death was linked to its gene thera...
This is a brutal but essential war story. An analyst slapped a $0 price target on drugmaker Sarepta after a third death was linked to its gene thera...
The stock barely moved after beating estimates and raising guidance. This is a masterclass in why you must look past the headline numbers and analys...
The traders are having a bare-knuckle debate about whether AI tools like Perplexity and ChatGPT are an existential threat to Google's cash-cow sea...
Everyone screams 'buy the dip!' but it's the laziest, most dangerous advice in investing! I'm tearing this cliché apart to show you why it work...
This is my personal secret sauce! I'm showing you how to build a 'dream team' watchlist of incredible companies that are too expensive... and then p...
Some companies are swapping their boring old cash reserves for Bitcoin, and it's one of the wildest corporate finance experiments in history! We're ...
This will blow your mind. A massive chunk, often 70-80%, of a company's calculated value comes from its 'terminal value' – a guess about its ...
Forget the noise! Professor Damodaran breaks down valuation into three simple, powerful pillars: Revenue Growth, Operating Margins, and Reinvestment...
ELEVEN MILLION COMPANIES! Are you hearing this?! This isn't your grandad's stock picking with a newspaper! This is TCV, a PIONEER of growth invest...